Wed, Sep 18 · 8:00

The exosome field is evolving rapidly as scientific understanding grows and the industry quickly approaches the stage of entering clinical trials over the coming years. If the boom in immunotherapies has told us anything about drug development; it’s being first to market is game changing.

The inaugural Exosome Based Therapeutic Development Summit 2019 will unite biotech, academia, pharma and technology providers to accelerate the discovery, development and commercialization of safe and effective exosome based therapeutics. As the race to the clinic intensifies, this summit focuses exclusively on therapeutic applications to help industry leaders and newcomers alike overcome key challenges to improve the end-to-end development of these therapeutics, from discovery through to the delivery of these products to market.

https://exosomebased-tx.com/

September 18th-19th, 2019

Contact:
info@hansonwade.com
+1 617 455 4188

Prices:

Drug Developer Conference Earlybird (Book by 05/24/19): USD 1599.0,
Drug Developer Conference (Standard rate): USD 2699.0,
Academic and Not-For-Profit Conference Earlybird (Book by 05/24/19): USD 899.0,
Academic and Not-For-Profit Conference (Standard rate): USD 1999.0

URL:

Brochure: https://go.evvnt.com/423796-0?pid=5731

Speakers: Linda Marban (Capricor Therapeutics), Richard Brudnick (Codiak Biosciences), Samir El-Andaloussi (Karolinska Institute and Evox Therapeutics), Shaun Stapleton (ReNeuron Limited), Xandra Breakefield (Harvard Medical School and Massachusetts General Hospital), Shelley Hartman (Aegle Therapeutics Corp.)